- Home
- IRIX vs CLDI Comparison
IRIX vs CLDI Comparison
Compare IRIX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRIX
- CLDI
- Stock Information
- Founded
- IRIX 1989
- CLDI 2014
- Country
- IRIX United States
- CLDI United States
- Employees
- IRIX N/A
- CLDI N/A
- Industry
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IRIX Health Care
- CLDI Health Care
- Exchange
- IRIX Nasdaq
- CLDI Nasdaq
- Market Cap
- IRIX 22.7M
- CLDI 20.2M
- IPO Year
- IRIX 1996
- CLDI N/A
- Fundamental
- Price
- IRIX $1.40
- CLDI $1.57
- Analyst Decision
- IRIX
- CLDI
- Analyst Count
- IRIX 0
- CLDI 0
- Target Price
- IRIX N/A
- CLDI N/A
- AVG Volume (30 Days)
- IRIX 113.5K
- CLDI 476.7K
- Earning Date
- IRIX 08-12-2025
- CLDI 08-08-2025
- Dividend Yield
- IRIX N/A
- CLDI N/A
- EPS Growth
- IRIX N/A
- CLDI N/A
- EPS
- IRIX N/A
- CLDI N/A
- Revenue
- IRIX $49,744,000.00
- CLDI N/A
- Revenue This Year
- IRIX $9.61
- CLDI N/A
- Revenue Next Year
- IRIX N/A
- CLDI N/A
- P/E Ratio
- IRIX N/A
- CLDI N/A
- Revenue Growth
- IRIX 0.09
- CLDI N/A
- 52 Week Low
- IRIX $0.78
- CLDI $1.51
- 52 Week High
- IRIX $2.04
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- IRIX 60.89
- CLDI 29.64
- Support Level
- IRIX $1.32
- CLDI $1.51
- Resistance Level
- IRIX $1.41
- CLDI $1.73
- Average True Range (ATR)
- IRIX 0.08
- CLDI 0.30
- MACD
- IRIX 0.01
- CLDI -0.03
- Stochastic Oscillator
- IRIX 80.56
- CLDI 1.66
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.